0000000000214413

AUTHOR

Axel Glasmacher

showing 3 related works from this author

Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors

2003

Morbidity and mortality in patients with malignancies, especially leukemia and lymphoma, are increased by invasive fungal infections. Since diagnosis of invasive fungal infection is often delayed, antifungal prophylaxis is an attractive approach for patients expecting prolonged neutropenia. Antifungal prophylaxis has obviously attracted much interest resulting in dozens of clinical trials since the late 1970s. The non-absorbable polyenes are probably ineffective in preventing invasive fungal infections, but may reduce superficial mycoses. Intravenous amphotericin B and the newer azoles were used in clinical trials, but their role in antifungal prophylaxis is still not well defined. Allogene…

0303 health sciencesmedicine.medical_specialty030306 microbiologybusiness.industryOpportunistic infectionItraconazoleHematologyGeneral MedicineNeutropeniamedicine.disease3. Good healthClinical trial03 medical and health sciences0302 clinical medicineAmphotericin BChemoprophylaxisImmunologyMedicine030212 general & internal medicinebusinessIntensive care medicineMycosisFluconazolemedicine.drugAnnals of Hematology
researchProduct

All-Trans Retinoic Acid and Gemtuzumab Ozogamicin as Adjunct To Salvage Therapy in Primary Refractory Acute Myeloid Leukemia: Results of Consecutive …

2005

Abstract Introduction: Response to first induction therapy is one of the most important prognostic factors in patients with adult myeloid leukemia (AML). Induction of CR or PR is the primary aim in these patients. Methods: Between 1993 and 2005 225 consecutive patients (median age: 48.4 yrs, range 16–60 yrs) treated within the AMLHD93 (n=45), AMLHD98A (n=157) and AMLSG 05-04 (n=23, still active) trials were evaluated. All patients had primary refractory AML after one cycle of ICE. The different salvage therapies were as follows: AMLHD93 sequential-HAM (S-HAM) for patients <55 years of age [cytarabine 3g/m2 bid. days 1,2,8,9, mitoxantrone 10mg/m2 days 3,4,10,11], HAM for patients >=55 …

medicine.medical_specialtyGemtuzumab ozogamicinmedicine.medical_treatmentImmunologySalvage therapyHematopoietic stem cell transplantationBiochemistryGastroenterology03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesInternal medicineMedicine030304 developmental biology0303 health sciencesMitoxantronebusiness.industryMyeloid leukemiaCell BiologyHematologyOdds ratio3. Good healthSurgeryTransplantation030220 oncology & carcinogenesisCytarabinebusinessmedicine.drugBlood
researchProduct

Economic evaluation of caspofungin vs liposomal amphotericin B for empirical therapy of suspected systemic fungal infection in the German hospital se…

2007

As antifungal agents are frequently used in hematology and oncology, economic data on the empirical therapy of suspected systemic fungal infection are pivotal. Data were analyzed according to: (1) the rate of nephrotoxicity related to treatment with caspofungin in comparison to liposomal amphotericin B (L-AmB) from a randomized clinical trial, (2) the effect of nephrotoxicity on length of hospital stay from a European observational study, and (3) an example of total bottom-up cost in a department of hematology in Germany. All estimates include 95% confidence intervals (CI) using two-stage Monte Carlo simulation on binominal and Gaussian random variables from separate studies with comparable…

medicine.medical_specialtyAntifungal AgentsLiposomal amphotericin Blaw.inventionNephrotoxicitychemistry.chemical_compoundEchinocandinsLipopeptidesRandomized controlled trialDouble-Blind MethodlawCaspofunginBottom-up studyAmphotericin BInternal medicineAmphotericin BGermanymedicineHumansLongitudinal StudiesProspective StudiesProspective cohort studyIntensive care medicineNephrotoxicitybusiness.industryGeneral MedicineHematologybacterial infections and mycosesConfidence intervalEconomic evaluationchemistryMycosesLiposomesNumber needed to treatCosts and Cost AnalysisObservational studyOriginal ArticleCaspofunginbusinessmedicine.drugAnnals of Hematology
researchProduct